Abstract： Objective To explore the clinical effect of rabeprazole combined with mosapride in the treatment of reflux esophagitis(RE).Methods A total of 76 RE patients admitted to Shanggao County People's Hospital from October 2021 to October 2023 were enrolled and randomly divided into two groups,38 cases in each group.The control group was treated with rabeprazole,and the observation group were treated rabeprazole combined with mosapride.The clinical efficacy,gastrointestinal hormones,inflammatory reaction,24 h esophageal pH monitoring,and adverse reactions were compared between the two groups.Results The total effective rate of the observation group(94.74%)was higher than that of the control group(78.95%)(P<0.05).There were no statistically significant difference in the gastrointestinal hormones,inflammatory reaction and 24 h esophageal pH monitoring of the two groups before treatment(P>0.05),after treatment,the gastrinb and motilin in the observation group were higher than those in the control group,vasoactive intestinal peptide was lower than that in the control group;interleukin(IL)-17、IL-6、IL-23、tumor necrosis factor-α in the observation group were lower than those in the control group;the number of reflux times,reflux duration≥5 min and the longest reflux duration in the observation group were less than those in the control group(P<0.05).There were no statistically significant difference in the adverse reactions of the two groups(P>0.05).Conclusion Rabeprazole combined with mosapride in the treatment of RE patients,which can reduce the inflammatory reaction,regulate gastrointestinal hormones,reduce the number of reflux,shorten the reflux time,and is safe and reliable.